biostudies-literatureUnknown4(5)Rikken SAOFCSL Behring LLC<h4>Background</h4>The AEGIS-II (ApoA-I Event Reducing in Ischemic Syndromes-II; NCT03473223) trial evaluated CSL112, a human plasma-derived apolipoprotein A-I therapy, for reducing cardiovascular events after acute myocardial infarction (AMI). Given CSL112's potential anti-inflammatory properties, we conducted an exploratory post hoc analysis to determine if its efficacy is influenced by baseline neutrophil-lymphocyte ratio (NLR), a marker of systemic inflammation, and low-density lipoprotein cholesterol (LDL-C).<h4>Objectives</h4>The purpose of this study was to investigate the association of baseline NLR and cardiovascular events and explore whether NLR and LDL-C modify CSL112's efficacy in post-AMI patients.<h4>Methods</h4>A total of 18,219 participants with AMI, multivessel coronary aJACC. Advances101727https://www.ebi.ac.uk/biostudies/studies/S-EPMC12059331biostudies-literatureImpact of Apolipoprotein A-I Infusions on Cardiovascular Events Post-MI by Neutrophil-Lymphocyte Ratio and LDL-Cholesterol Levels.PMC12059331Korjian SSteg PGWhite Hvan 't Hof AWJMahaffey KWAEGIS-II Committees and InvestigatorsCornel JHChi GAnschuetz GDuffy DGoodman SGTen Berg JMNicholls SJLopes RDKingwell BAGibson CMBahit MCMehran RRidker PMRikken SAOFOphuis TOBainey KRHarrington RANicolau JCLewis BSVinereanu DLibby PMohammadnia NBode CEl Messaoudi SfalseImpact of Apolipoprotein A-I Infusions on Cardiovascular Events Post-MI by Neutrophil-Lymphocyte Ratio and LDL-Cholesterol Levels.<h4>Background</h4>The AEGIS-II (ApoA-I Event Reducing in Ischemic Syndromes-II; NCT03473223) trial evaluated CSL112, a human plasma-derived apolipoprotein A-I therapy, for reducing cardiovascular events after acute myocardial infarction (AMI). Given CSL112's potential anti-inflammatory properties, we conducted an exploratory post hoc analysis to determine if its efficacy is influenced by baseline neutrophil-lymphocyte ratio (NLR), a marker of systemic inflammation, and low-density lipoprotein cholesterol (LDL-C).<h4>Objectives</h4>The purpose of this study was to investigate the association of baseline NLR and cardiovascular events and explore whether NLR and LDL-C modify CSL112's efficacy in post-AMI patients.<h4>Methods</h4>A total of 18,219 participants with AMI, multivessel coronary a2025-01-01T00:00:00Z2025 May2026-06-01T05:23:25.707Z2026-04-08T09:36:12.868ZS-EPMC120593314028808310.1016/j.jacadv.2025.101727